Dr. Reddy’s Of India To Withdraw From Small Markets
This article was originally published in PharmAsia News
Executive Summary
India's Dr. Reddy's Laboratories plans to abandon small pharmaceutical markets around the world and concentrate on larger ones. According to Dr. Reddy's, the small markets account for less than one percent of the generics maker's revenues. A company spokesman said the withdrawal already is occurring in some countries across all regions of the world. Managing Director and COO Satish Reddy said the move is being made so the firm can be more assertive in key markets, redeploying its resources accordingly. The firm counts the United States, India, Russia, former Soviet republics and Germany as contributing 90 percent of its global revenues. (Click here for more
You may also be interested in...
Sumitomo To Reprioritize Pipeline After Ulotaront’s Phase III Fail
Sumitomo Pharma is to focus more on late-stage candidates in oncology and cell/gene therapy while passing on full global rights for ulotaront and SEP-380135 to Otsuka.
Lilly, BMS, Microsoft On GenAI’s Machine-First Approach Success, Cell Therapy Use, Regulation
As Eli Lilly chief information and digital officer Rau speaks of generative AI models training humans on drug discovery, Bristol Myers Squibb CDTO Meyers of wearables aiding cell therapy and Microsoft Research India MD Rajamani of interoperability no longer being a huge challenge, a discussion at the BioAsia summit highlights a fundamental shift in R&D approaches.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.